MARATTO

article · Zenodo (CERN European Organization for Nuclear Research)

Ameliorative effect of Hibiscus sabdariffa leaf flavonoid extract on the PSA/CEA/AKT/MMP‑9 signaling pathway in benign prostatic hyperplasia‑induced rats

Abstract

Benign prostatic hypertrophy (BPH) is a prevalent condition affecting the prostate gland of elderly men. This study investigated the effects of H. sabdariffa leaf flavonoid extracts on BPH induction in rats. Thirty-six male Wistar rats were split into six groups: normal controls, BPH-induced rats (3 mg/kg testosterone), and rats treated with BPH-induced with flavonoid extract (300 mg/kg and 150 mg/kg) or a standard drug (1 mg/kg finasteride). After 28 days, biochemical, histological, and molecular parameters were assessed. The extract rich in flavonoids from H. sabdariffa markedly (p < 0.05) decreased the amount of MDA and enhanced the activities of antioxidant enzymes in rats administered with BPH. The extracts substantially attenuated inflammatory markers such as IL-6, IL-1β, and TNFα levels. Histological examination revealed improved prostate architecture in the treated groups in contrast to those in BPH-induced rats. Additionally, substantial (p < 0.05) downregulation of CEA, AKT, MMP9, and PSA in the extract-treated groups was observed. HPLC characterization identified prominent flavonoids, with quercetin being the most abundant bioactive compound. The outcome of this study proffers the therapeutic activities of H. sabdariffa flavonoid extract on BPH rat model.

Research topics

  • Hibiscus Plant Research Studies
  • Hops Chemistry and Applications
  • Natural Products and Biological Research

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.5281/zenodo.18280232

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.